MCID: MTR002
MIFTS: 47

Mitral Valve Insufficiency

Categories: Cardiovascular diseases

Aliases & Classifications for Mitral Valve Insufficiency

MalaCards integrated aliases for Mitral Valve Insufficiency:

Name: Mitral Valve Insufficiency 12 43 15 71
Mitral Regurgitation 12 29 54 6 15
Congenital Insufficiency of Mitral Valve 12 71
Congenital Mitral Insufficiency 12 32
Congenital Mitral Regurgitation 12
Mitral Valve Incompetence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11502
ICD9CM 34 396.3 746.6
MeSH 43 D008944
SNOMED-CT 67 29928006 48724000
ICD10 32 Q23.3
UMLS 71 C0026266 C0158619 C0264774

Summaries for Mitral Valve Insufficiency

MalaCards based summary : Mitral Valve Insufficiency, also known as mitral regurgitation, is related to inferior myocardial infarction and systolic heart failure. An important gene associated with Mitral Valve Insufficiency is TBX5 (T-Box Transcription Factor 5), and among its related pathways/superpathways is Renin secretion. The drugs Ranolazine and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney.

Related Diseases for Mitral Valve Insufficiency

Diseases in the Mitral Valve Disease family:

Mitral Valve Insufficiency

Diseases related to Mitral Valve Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 424)
# Related Disease Score Top Affiliating Genes
1 inferior myocardial infarction 31.5 PRB1 NPPB IL4I1
2 systolic heart failure 31.4 NPPB NPPA CRP ACE
3 atrioventricular block 31.4 TNNI3 TBX5 NPPB ACE
4 cardiogenic shock 31.2 NPPB CRP
5 coronary stenosis 31.2 TNNI3 NPPB CRP ACE
6 posterolateral myocardial infarction 31.2 TNNI3 PRB1 ARSL
7 intermediate coronary syndrome 31.1 TNNI3 REN CRP ACE
8 ventricular septal defect 31.0 TBX5 NPPB NPPA MIR423
9 left bundle branch hemiblock 31.0 TNNI3 NPPB MYBPC3 CRP ACE
10 pericarditis 31.0 TNNI3 NPPB CRP ACE
11 angina pectoris 30.9 TNNI3 NPPB CRP ACE
12 heart septal defect 30.9 TNNI3 TBX5 NPPA MIR423 ELN
13 aortic aneurysm 30.9 FBN1 ELN CRP ACE
14 rheumatic heart disease 30.9 NPPB ELN ACE
15 anterolateral myocardial infarction 30.9 NPPB NPPA ACE
16 coronary artery vasospasm 30.8 TNNI3 CRP ACE
17 sleep apnea 30.8 REN NPPB CRP ACE
18 vascular disease 30.8 REN NPPB ELN CRP ACE
19 respiratory failure 30.7 REN NPPB NPPA CRP ACE
20 aortic valve disease 1 30.7 TBX5 FBN1 ELN ACE
21 supravalvular aortic stenosis 30.7 PDLIM1 FBN1 ELN
22 aortitis 30.6 ELN CRP
23 constrictive pericarditis 30.6 TNNI3 NPPB CRP ARSL ACE
24 hypertensive heart disease 30.6 REN NPPB NPPA ACE
25 congestive heart failure 30.6 TNNI3 REN NPPB NPPA CRP ACE
26 systemic scleroderma 30.6 FBN1 ELN CRP ACE
27 pulmonary edema 30.6 TNNI3 REN NPPB NPPA CRP ACE
28 end stage renal failure 30.5 REN NPPB NPPA CRP ACE
29 restrictive cardiomyopathy 30.5 TNNI3 NPPB MYBPC3 ACE
30 cerebrovascular disease 30.5 REN NPPB NPPA CRP ACE
31 silent myocardial infarction 30.5 TNNI3 CRP ACE
32 aortic aneurysm, familial abdominal, 1 30.5 FBN1 ELN CRP ACE
33 myocarditis 30.5 TNNI3 NPPB NPPA ACE
34 intracranial embolism 30.5 CRP ACE
35 first-degree atrioventricular block 30.5 CRP ACE
36 wolff-parkinson-white syndrome 30.4 TNNI3 TBX5 NPPB MYBPC3
37 carotid artery disease 30.4 REN CRP ACE
38 aortic aneurysm, familial thoracic 1 30.4 FBN1 ELN ACE
39 central sleep apnea 30.4 REN NPPB NPPA CRP ACE
40 aortic disease 30.4 REN FBN1 ELN CRP ACE
41 pulmonary embolism 30.4 TNNI3 NPPB NPPA CRP ACE
42 chronic kidney disease 30.4 TNNI3 REN NPPB NPPA CRP ACE
43 acute myocarditis 30.4 TNNI3 NPPB CRP ACE
44 uremia 30.3 REN CRP ACE
45 inguinal hernia 30.3 FBN1 ELN ACE
46 cardiac tamponade 30.3 TNNI3 REN NPPB IL4I1 CRP ACE
47 orthostatic intolerance 30.3 TBX5 PDLIM1 MIR423 FBN1 ELN ACE
48 connective tissue disease 30.3 MIR423 FBN1 ELN CRP ACE
49 stroke, ischemic 30.2 REN NPPB NPPA FBN1 CRP ACE
50 arteriosclerosis 30.2 FBN1 ELN CRP ACE

Graphical network of the top 20 diseases related to Mitral Valve Insufficiency:



Diseases related to Mitral Valve Insufficiency

Symptoms & Phenotypes for Mitral Valve Insufficiency

Drugs & Therapeutics for Mitral Valve Insufficiency

Drugs for Mitral Valve Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
2
Warfarin Approved Phase 4 81-81-2 6691 54678486
3
Atorvastatin Approved Phase 4 134523-00-5 60823
4
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
5
Dobutamine Approved Phase 4 34368-04-2 36811
6
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
7
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
11
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
12
Cosyntropin Approved Phase 4 16960-16-0 16129617
13
Etomidate Approved Phase 4 33125-97-2 36339 667484
14
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
15
Racepinephrine Approved Phase 4 329-65-7 838
16
Flavin Mononucleotide Approved, Investigational Phase 4 146-17-8 643976
17
Ethanol Approved Phase 4 64-17-5 702
18
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
19
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
20
Norepinephrine Approved Phase 4 51-41-2 439260
21
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
22
tannic acid Approved Phase 4 1401-55-4
23
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
24
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
25
Metolazone Approved Phase 4 17560-51-9 4170
26
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
27
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
28
Dabigatran Investigational Phase 4 211914-51-1
29
Candesartan Experimental Phase 4 139481-59-7 2541
30
Simendan Investigational Phase 4 131741-08-7
31 Sodium Channel Blockers Phase 4
32 Endorphins Phase 4
33 Melanocyte-Stimulating Hormones Phase 4
34 beta-endorphin Phase 4
35 Adrenocorticotropic Hormone Phase 4
36 Antithrombins Phase 4
37 Antithrombin III Phase 4
38 Antioxidants Phase 4
39 Omega 3 Fatty Acid Phase 4
40 Hypolipidemic Agents Phase 4
41 Anticholesteremic Agents Phase 4
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
43 Antimetabolites Phase 4
44 Lipid Regulating Agents Phase 4
45 Adrenergic Antagonists Phase 4
46 Adrenergic beta-Antagonists Phase 4
47 Antihypertensive Agents Phase 4
48 Adrenergic beta-1 Receptor Antagonists Phase 4
49 Adrenergic Agents Phase 4
50 Autonomic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 321)
# Name Status NCT ID Phase Drugs
1 The Effect of Different Surgical Methods in the Treatment of Patients With Ischemic Mitral Regurgitation and Assess the Dynamics of Heart Failure and the Effectiveness of Surgical Treatment of Mitral Valve. Unknown status NCT01368575 Phase 4
2 Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
3 Interventional Strategy to Abrogate Mitral Regurgitation Using the MitraClip System in High-Risk Patients Considered Unsuitable for Surgery (ISAR-CLIP) Unknown status NCT01431222 Phase 4
4 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Unknown status NCT02592889 Phase 4
5 Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4 antithrombin III
6 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
7 Mitigating Cardiac Inflammation and Oxidative Stress in Atrial Myocardium Via Short-term Lovaza Treatment Prior to Surgery Unknown status NCT01046604 Phase 4 Lovaza group
8 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
9 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
10 Angiotensin-II Blockade in Mitral Regurgitation Completed NCT00587470 Phase 4 Candesartan;atacand;Placebo
11 Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C Completed NCT02687932 Phase 4 LCZ696;Valsartan
12 Beta Blockade in Mitral Regurgitation Completed NCT00166400 Phase 4 metoprolol succinate
13 Colvin-Galloway Future® Annuloplasty Ring/Band Clinical Trial: Interventional Multi-center Prospective Clinical Outcome Study Completed NCT01074671 Phase 4
14 Study of Paravertebral Block for Cardiac Surgery Completed NCT02180893 Phase 4
15 Effect of an Anesthetic Induction Dose of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery Completed NCT00415701 Phase 4 Etomidate;Propofol;Hydrocortisone;NaCl 0.9%
16 Clinical and Ultramicroscopic Myocardial Randomized Study of On-Pump Beating Heart Mitral Valve Replacement Completed NCT01641614 Phase 4
17 Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery Completed NCT01595737 Phase 4 Levosimendan;Placebo
18 Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
19 Survival of Patients With Primary Prophylactic ICD Indication, Provided With Intensified Care After 1st ICD Therapy Completed NCT00619593 Phase 4
20 The Effects of Levosimendan on Renal Function in Patients With Low Ejection Fraction Undergoing Mitral Valve Surgery. Completed NCT01969071 Phase 4 Levosimendan;Dobutamine
21 Effects of High Furosemide Doses Alone or With Hypertonic Saline on Troponin I Myocardial Release in Acute Decompensated Heart Failure: a Double Blind Study. Completed NCT01419132 Phase 4 Furosemide;Furosemide
22 Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET) Completed NCT02261948 Phase 4 Levosimendan;Placebo
23 Peripheral Nerve Blocks for Major Lower Extremity Amputations Not yet recruiting NCT03174782 Phase 4 Bupivacaine;Saline Solution
24 High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Randomized Controlled Trial Comparing MitraClip® to Surgical Therapy Terminated NCT02534155 Phase 4
25 Effect of Protocolized Diuretic Strategy on Clinical Outcomes and Health-related Quality of Life in Cardiorenal Failure: A Randomized Trial Terminated NCT01921829 Phase 4 Protocolized Diuretic Strategy
26 Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders (TORSION). A Randomized Comparison of Torsion-imaging Guided Optimization vs. Usual Settings. Unknown status NCT00867984 Phase 3
27 Randomized Evaluation of Mitral Annuloplasty During Coronary Artery Bypass Grafting for Moderate Functional Ischaemic Mitral Regurgitation. Completed NCT00413998 Phase 3
28 Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease) Completed NCT01052428 Phase 2, Phase 3 metoprolol succinate (Toprol XL);Placebo
29 Clinical Investigation Of The Sorin 3D Annuloplasty Ring For Mitral Repair Completed NCT00567853 Phase 3
30 Comparative Effects of Brief Inhaled Milrinone Versus Intravenous Milrinone on Pulmonary Arterial Pressure in Patients Undergoing Mitral Valve Surgery Completed NCT01621971 Phase 3 inhaled milrinone;intravenous milrinone
31 A Prospective Canadian Multi-Center Randomized Study; Spontaneous AtrioVEntricular Conduction PReservation Completed NCT01219621 Phase 3
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure Completed NCT00270374 Phase 3 nesiritide
33 A Prospective Phase III Parallel, Randomised Controlled Trial Using Double-bolus Recombinant Staphylokinase (THR-100) vs Streptokinase in Patients With Acute Myocardial Infarction Completed NCT01305226 Phase 3 THR-100;Streptokinase
34 Echocardiography-Guided Hemodynamic Management Strategy for Patients Requiring Perioperative Care for Non-Cardiac Surgery Completed NCT01050361 Phase 3
35 BOsentan for Mild Pulmonary Vascular Disease in Asd Patients (the BOMPA Trial): a Double-blind, Randomized Controlled, Pilot Trial Completed NCT01218607 Phase 3 Bosentan;Placebo
36 Prospective Evaluation Of Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery Completed NCT00321295 Phase 3
37 Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System Compared to Abbott MitraClip in Patients With Mitral Regurgitation Recruiting NCT03706833 Phase 3
38 Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride Recruiting NCT03270514 Phase 3 Exparel Injectable Product;Bupivacaine Hydrochloride
39 Multicentre Randomized Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation. Active, not recruiting NCT01920698 Phase 3
40 Safety and Efficacy of Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure Suspended NCT00815386 Phase 2, Phase 3
41 Trial of ACE Inhibition in Children With Mitral Regurgitation After Repair of AVSD Terminated NCT00113698 Phase 3 Enalapril
42 Surgery Versus Medical Treatment Alone for Patients With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure: SMMART-HF Terminated NCT00608140 Phase 3 Optimal medical therapy (OMT)
43 A Multicenter, Randomized, Open-label, Non-inferiority Phase III Study, Between Low-Molecular Weight Heparins, Versa® (Enoxaparin - Eurofarma) and Clexane® (Enoxaparin - Sanofi-Aventis), in Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation. Terminated NCT01356992 Phase 3 Enoxaparin
44 Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation Unknown status NCT00833014 Phase 2
45 Phase II Study of Using a New Device (Neochordameter) in Making Artificial Chordae for Mitral Valve Repair Unknown status NCT01811537 Phase 1, Phase 2
46 A Study of the Evalve Cardiovascular Valve Repair System Endovascular Valve Edge-to-Edge REpair STudy (EVEREST I). Completed NCT00209339 Phase 1, Phase 2
47 An Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device Used to Reduce Mitral Regurgitation Completed NCT00572091 Phase 1, Phase 2
48 Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve (RESTOR-MV) Completed NCT00120276 Phase 2
49 Valtech Cardinal Adjustable Semi-Rigid Annuloplasty Ring System For Treatment of Mitral Valve Regurgitation in Open Surgical Repair Completed NCT01137734 Phase 2
50 Evaluation of Outcomes Following Mitral Valve Repair/Replacement in Severe Chronic Ischemic Mitral Regurgitation Completed NCT00807040 Phase 2

Search NIH Clinical Center for Mitral Valve Insufficiency

Cochrane evidence based reviews: mitral valve insufficiency

Genetic Tests for Mitral Valve Insufficiency

Genetic tests related to Mitral Valve Insufficiency:

# Genetic test Affiliating Genes
1 Mitral Regurgitation 29

Anatomical Context for Mitral Valve Insufficiency

MalaCards organs/tissues related to Mitral Valve Insufficiency:

40
Heart, Testes, Kidney, Lung, Brain, Endothelial, Liver

Publications for Mitral Valve Insufficiency

Articles related to Mitral Valve Insufficiency:

(show top 50) (show all 14596)
# Title Authors PMID Year
1
Relationship between the tissue Doppler-derived Tei index and plasma brain natriuretic peptide levels in patients with mitral regurgitation. 54 61
20329488 2010
2
Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. 54 61
19996017 2009
3
Tei index correlates with tissue Doppler parameters and reflects neurohormonal activation in patients with an abnormal transmitral flow pattern. 54 61
19558518 2009
4
BNP in mitral valve restrictive annuloplasty for ischemic mitral regurgitation. 54 61
18657328 2009
5
Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. 54 61
19744620 2009
6
Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease. 54 61
19282651 2009
7
Successful catheter ablation to accessory atrioventricular pathway as cardiac resynchronization therapy in a patient with dilated cardiomyopathy. 54 61
19028709 2009
8
Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trial. 54 61
18926439 2008
9
Dynamic left ventricular dyssynchrony contributes to B-type natriuretic peptide release during exercise in patients with systolic heart failure. 54 61
18319268 2008
10
Correlation of the myocardial performance index with plasma B-type natriuretic peptide levels in patients with mitral regurgitation. 54 61
17541723 2008
11
Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation. 54 61
18202251 2008
12
The combination of B-type natriuretic peptide and C-reactive protein provides incremental prognostic value among older patients referred for cardiac catheterization. 54 61
17617749 2007
13
Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. 54 61
16959341 2007
14
Usefulness of the brain natriuretic peptide to atrial natriuretic peptide ratio in determining the severity of mitral regurgitation. 54 61
17380223 2007
15
Significance of brain natriuretic peptide in the evaluation of symptoms and the degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. 54 61
17243506 2006
16
Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation. 54 61
16563910 2006
17
Predictors of remodeling in the CRT era: influence of mitral regurgitation, BNP, and gender. 54 61
16624682 2006
18
Efficacy of nasal bi-level positive airway pressure in congestive heart failure patients with cheyne-stokes respiration and central sleep apnea. 54 61
16041159 2005
19
B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. 54 61
15883225 2005
20
Clinical applications of B-type natriuretic peptide levels in the care of cardiovascular patients. 54 61
15729209 2004
21
Changes in type B natriuretic peptide (BNP) concentrations during cardiac valve replacement. 54 61
15144992 2004
22
Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. 54 61
15013124 2004
23
[Autoantibodies: new upstream targets of paroxysmal atrial fibrillation in patients with congestive heart failure]. 54 61
12463096 2002
24
Atrial natriuretic factor and mitral valve prolapse syndrome. 54 61
11533551 2001
25
Acute mitral regurgitation due to chordal rupture in a patient with neonatal Marfan syndrome caused by a deletion in exon 29 of the FBN1 gene. 54 61
10441700 1999
26
Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. 54 61
10379945 1999
27
Hemodynamic correlates of atrial natriuretic peptide concentration in unselected patients with heart disease of different etiologies. 54 61
9887389 1998
28
Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in patients with heart failure. 54 61
9283534 1997
29
Associations between atrial natriuretic peptides, echocardiographic findings and mortality in an elderly population sample. 54 61
9159597 1997
30
Plasma atrial natriuretic peptide is elevated in patients with hypertrophic cardiomyopathy. 54 61
8842784 1996
31
Ventricular adenine nucleotide translocator mRNA is upregulated in dilated cardiomyopathy. 54 61
8252591 1993
32
A new and rare form of Williams' syndrome. 54 61
8351994 1993
33
[Correlations between plasma concentrations of atrial natriuretic factor and right ventricular function in patients with severe cardiac failure]. 54 61
1532302 1992
34
Dynamics of creatine kinase shuttle enzymes in the human heart. 54 61
1909638 1991
35
[Supravalvular aortic stenosis syndrome with advanced mitral regurgitation requiring extended aortoplasty and mitral valve replacement: a case report]. 54 61
2038171 1991
36
Is there a problem with respect? Risk of neochordal rupture. 61
31834031 2020
37
Perioperative Management of Patients with Sepsis and Septic Shock, Part II: Ultrasound Support for Resuscitation. 61
32008647 2020
38
Author's reply to: Worsening of mitral regurgitation following transcatheter aortic valve replacement. 61
31870782 2020
39
Afterload Mismatch After MitraClip Implantation: Intraoperative Assessment and Prognostic Implications. 61
32024805 2020
40
Validation of non-invasive ramp testing for HeartMate 3. 61
32037731 2020
41
Attenuated Mitral Leaflet Enlargement Contributes to Functional Mitral Regurgitation After Myocardial Infarction. 61
32000951 2020
42
Atrial fibrillation is not an independent predictor of outcome in patients with aortic stenosis. 61
31439661 2020
43
A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months. 61
32024277 2020
44
Elevated antistreptolysin O titer is closely related to cardiac mitral insufficiency in untreated patients with Takayasu arteritis. 61
32013899 2020
45
Familial occurrence of mitral regurgitation in patients with mitral valve prolapse undergoing mitral valve surgery. 61
31475862 2020
46
Minimally Invasive Nonresectional Mitral Valve Repair Can Be Performed With Excellent Outcomes. 61
31473178 2020
47
Automated Implantation of Artificial Mitral Chords: Preliminary Results From the Feasibility Trial. 61
31563490 2020
48
Multiple left atrium diverticula and mitral regurgitation in a child. 61
32031607 2020
49
Outcomes of mitral valve surgery for severe ischemic mitral regurgitation. 61
31821618 2020
50
Transesophageal echocardiography in minimally invasive cardiac surgery. 61
31789893 2020

Variations for Mitral Valve Insufficiency

ClinVar genetic disease variations for Mitral Valve Insufficiency:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;inv(6)(p22q13)dninversion Pathogenic 267941
2 TBX5 NM_000192.3(TBX5):c.1221C>G (p.Tyr407Ter)SNV Pathogenic 495227 rs1555223259 12:114793673-114793673 12:114355868-114355868
3 FBN1 NM_000138.4(FBN1):c.8016T>G (p.Cys2672Trp)SNV Likely pathogenic 374081 rs1057518883 15:48707768-48707768 15:48415571-48415571
4 FBN1 NM_000138.4(FBN1):c.478T>C (p.Cys160Arg)SNV Likely pathogenic 374203 rs1057518973 15:48888540-48888540 15:48596343-48596343
5 MYH11 NM_002474.3(MYH11):c.4360G>C (p.Asp1454His)SNV Likely pathogenic 374162 rs1057518938 16:15818023-15818023 16:15724166-15724166
6 46;XX;inv(14)(q24.1q32.1)dninversion Uncertain significance 267889

Expression for Mitral Valve Insufficiency

Search GEO for disease gene expression data for Mitral Valve Insufficiency.

Pathways for Mitral Valve Insufficiency

Pathways related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.64 REN NPPA ACE

GO Terms for Mitral Valve Insufficiency

Cellular components related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 REN NPPB NPPA MIR423 FBN1 CRP
2 extracellular region GO:0005576 9.32 REN PRB1 NPPB NPPA IL4I1 FBN1
3 cardiac myofibril GO:0097512 9.16 TNNI3 MYBPC3

Biological processes related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.63 REN FBN1 ACE
2 heart development GO:0007507 9.56 TNNI3 TBX5 PDLIM1 FBN1
3 heart contraction GO:0060047 9.43 TNNI3 ACE
4 amyloid-beta metabolic process GO:0050435 9.4 REN ACE
5 negative regulation of systemic arterial blood pressure GO:0003085 9.37 NPPB NPPA
6 angiotensin maturation GO:0002003 9.32 REN ACE
7 cGMP biosynthetic process GO:0006182 9.16 NPPB NPPA
8 receptor guanylyl cyclase signaling pathway GO:0007168 8.96 NPPB NPPA
9 regulation of blood pressure GO:0008217 8.92 REN NPPB NPPA ACE

Molecular functions related to Mitral Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.33 NPPB NPPA FBN1
2 extracellular matrix constituent conferring elasticity GO:0030023 8.96 FBN1 ELN
3 hormone receptor binding GO:0051427 8.62 NPPB NPPA

Sources for Mitral Valve Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....